CAR-T Cell

CAR-T (chimeric antigen receptor T-cell) therapy is a form of immunotherapy in which a patient's own T cells are collected, genetically reprogrammed in a lab to recognize a specific protein on cancer cells, and then infused back into the body to attack the tumor. For mesothelioma, researchers are testing CAR-T cells engineered to target mesothelin, a protein found on the surface of most mesothelioma cells. The treatment is currently available for mesothelioma only through clinical trials.

Origin

The concept emerged from work by Zelig Eshhar in Israel in the late 1980s and was advanced clinically by Carl June and colleagues at the University of Pennsylvania in the 2010s. The first CAR-T therapies were approved by the FDA in 2017 for certain blood cancers; adapting the approach to solid tumors like mesothelioma has been the focus of ongoing research.

Significance in Asbestos Context

For mesothelioma patients, CAR-T is one of the most actively studied experimental options when standard chemotherapy, surgery, and immune checkpoint inhibitors (such as nivolumab plus ipilimumab) stop working. Most mesothelioma CAR-T trials target mesothelin and are delivered directly into the pleural space (intrapleural infusion) rather than through a vein, which has shown encouraging early results at centers like Memorial Sloan Kettering and the University of Pennsylvania. Because CAR-T is investigational for mesothelioma, access usually requires enrolling in a clinical trial, and trial participation, travel costs, and supportive care should be discussed with both your oncology team and your legal team. These expenses may be recoverable as damages in an asbestos claim.

Example Sentence

"After her pleural mesothelioma progressed on chemotherapy, she was evaluated for a mesothelin-directed CAR-T cell trial at a specialized cancer center."

Related Terms

Immunotherapy, Mesothelin, Mesothelioma, Checkpoint Inhibitor, Clinical Trial, Pleural Mesothelioma

Notes

• Ask your oncologist whether you are a candidate for a mesothelin-targeted CAR-T trial; ClinicalTrials.gov and the Mesothelioma Applied Research Foundation maintain searchable listings.
• Request that your tumor be tested for mesothelin expression. Most mesothelioma trials require this as an eligibility criterion.
• Be prepared for serious potential side effects including cytokine release syndrome (CRS), neurotoxicity (ICANS), and on-target/off-tumor effects; ask about the trial site's experience managing these complications.
• Keep detailed records of all trial-related costs, travel, and lodging. These are often compensable in asbestos litigation and may also be partially covered by trial sponsors or patient-assistance programs.
• Confirm that participating in a trial will not jeopardize coverage of your standard care; ask the trial coordinator for a written summary of what the sponsor pays for versus what your insurance is billed.